Trial Profile
A study to investigate efficacy of neoadjuvant Sorafenib treatment on tumor cluster shedding in patients with renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 05 Mar 2010 Results were presented at the ASCO 2010 Genitourinary Cancers Symposium.
- 05 Mar 2010 New trial record